Corneal Dystrophy, Crystalline, of Schnyder

REDWOOD CITY, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced that the first patient has been dosed in a Phase 1 trial evaluating briquilimab as second-line therapy in subjects with lower-risk myelodysplastic syndrome. “The initiation of this trial in LR-MDS represents a significant milestone in our briquilimab development program,” said Ronald Martell, President and Chief Executive Officer of Jasper. “To date, the potential of briquilimab has been clinically assessed across five transplant indications and we are excited to explore its potential as a treatment option for a chronic disease such as LR-MDS. This trial underscores our commitment to improving outcomes and quality of life for patients with rare and chronic diseases driven by mast and stem cells.” Jeffery Lancet, M.D., Chair of the Department of Malignant Hematology at Moffitt Cancer Center, where the Phase 1 trial is being conducted, added, “LR-MDS patients often face limited treatment options that primarily focus on increasing blood cell production and survival rather than restoring normal blood homeostasis. By directly targeting and depleting the diseased stem cells, briquilimab has the potential to restore bone marrow to a healthier and more functional state, with the ultimate goal of improved long-term outcomes and quality of life. We are excited to test briquilimab in the LR-MDS setting.” Edwin J. Tucker, M.D., Chief Medical Officer of Jasper, stated, “There is a significant need for therapies for people living with LR-MDS. While certain treatments could be employed to manage the symptoms, they do not typically target diseased cells or offer a comprehensive therapeutic approach. With its compelling therapeutic potential in targeting c-Kit, briquilimab holds great promise in lower-risk MDS and could provide a profound benefit for patients in dire need of new therapies. We are excited to embark on this clinical journey and contribute to the advancement of treatment options for patients with chronic diseases.” The open-label, single-arm Phase 1 trial will evaluate the safety and tolerability of briquilimab as a second-line therapy in subjects with LR-MDS. The trial will employ a 3+3 dose escalation design to identify the maximum tolerated dose or optimal biologic dose and recommended Phase 2 dose of briquilimab monotherapy as a chronic therapeutic for LR-MDS patients with documented cytopenia such as red blood cell transfusion dependence, thrombocytopenia or neutropenia. The trial will be conducted at Moffitt Cancer Center in Tampa, FL, and is expected to enroll up to 30 patients that will receive briquilimab every 56 days for 4 consecutive cycles. For more information on the Phase 1 trial of briquilimab for the treatment of LR-MDS please visit clinicaltrials.gov and reference identifier: NCT05903274. About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at www.jaspertherapeutics.com. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, its potential to restore bone marrow, its potential to improve long-term outcomes and quality of life, its therapeutic potential to target c-Kit, its potential profound benefit for patients in dire need of new therapies, its potential to contribute to the advancement of treatment options for patients with chronic diseases and its ability to target and deplete the diseased stem cells, the development of briquilimab, Jasper’s commitment to improving outcomes and quality of life for patients with rare and chronic diseases driven by mast and stem cells and Jasper’s expectations regarding the timing of, recruitment for and dosing in the clinical trial. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior trial results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts:John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com

WASHINGTON, June 20, 2023 /PRNewswire/ -- On behalf of the Association of Black Cardiologists (ABC), we extend our heartfelt well wishes and unwavering support to National Football League (NFL) player Damar Hamlin, who experienced a sudden cardiac event early this year. We recognize the gravity of this event and its impact on him, the NFL community, the country, and the world. Damar's strength and resilience are commendable, and his dedication to sudden cardiac death awareness is inspiring. While our team members were not directly involved in his evaluation, we agree that a diagnosis of commotio cordis is the most likely if a comprehensive cardiac evaluation was normal. Commotio cordis occurs when there is an untimely, focal, high-velocity impact to the chest wall during a narrow, vulnerable period of the cardiac cycle. This diagnosis is extremely rare, and can occur in a normal heart. The decision regarding the resumption of competitive sports should be predicated upon a meticulous appraisal of Damar's specific condition, the underlying etiology of the cardiac event, and the potential risks at stake. The ABC ardently advocates for the principles of shared decision-making in sports cardiology, wherein medical professionals collaborate with the athlete, their family, the organization, and a multidisciplinary team to ascertain the safest course of action regarding return-to-play. With appropriate medical care, rehabilitation, and understanding of risk, we support him returning to the NFL if he so wishes. Additionally, we pray that he receives the full support of the NFL and the nation for his psychological recovery. Sudden cardiac death (SCD) is a complex event with many potential underlying mechanisms that may lead to a sudden cessation of effective cardiac pumping and loss of pulse. In individuals predisposed to SCD, the pathophysiology involves a combination of structural abnormalities of the heart, inherited cardiac conditions, and electrical disturbances. In an attempt to detect cardiac abnormalities that increase an athlete's risk of exercise-related SCD, preparticipation evaluations (PPE) can be helpful. However, despite best efforts and screening, tragic events may still occur. Once abnormalities are identified on screening, appropriate downstream testing is required. It is crucial to acknowledge the disparities that exist in the diagnosis of predisposing conditions related to SCD. Specific populations, particularly Black individuals, face inequities in accessing comprehensive downstream cardiac evaluations, including imaging, stress testing, genetic testing, and advanced invasive diagnostic modalities. This can impede the identification of underlying cardiac conditions, thereby hindering targeted prevention strategies. Furthermore, disparities in sudden cardiac arrest and resuscitation outcomes have been observed, with lower survival rates among certain racial and ethnic groups. Epidemiological studies, including that by the National Collegiate Athletic Association (NCAA), have highlighted Black male athletes as the highest-risk individuals compared to white athletes. To date, there has been no biological explanation for these discrepancies. The ABC asserts that addressing adverse social determinants of health is necessary to achieve equitable healthcare and rectify these disparities to ensure the well-being of all athletes. It is essential to acknowledge the excellent, immediate resuscitation that Damar Hamlin received on an NFL field with athletic trainers skilled in cardiopulmonary resuscitation (CPR), automated external defibrillator (AED) use, and emergency medical transport. It exemplified the well-executed emergency action plan (EAP) that every sporting facility and organization is encouraged to have. Unfortunately, millions of student-athletes throughout this country are not afforded these resources, mainly in impoverished environments especially in Black and Hispanic communities. Lack of athletic trainers and functioning AEDs leads to less survival among these athletes. The ABC endorses and supports the Access to AEDs Act. This bipartisan bill will increase access to life-saving equipment, CPR education, and training for schools nationwide to improve outcomes of sudden cardiac arrest for all. The ABC remains unwavering in our commitment to raising awareness regarding sudden cardiac risk in athletes, promoting comprehensive cardiac evaluations regardless of socioeconomic background, and advocating for equitable access to cardiac care. We implore athletes, sports organizations, medical professionals, and the wider community to unite in mitigating the risks associated with sports-related cardiac events, thereby ensuring the safety and well-being of all athletes. Merije Chukumerije, MD; ABC member, Sports Cardiology specialist; Marlon E. Everett, MD, Co-Chair, ABC Communications Committee; Camille G. Frazier-Mills, MD, MHS, Co-Chair, ABC Electrophysiology Committee; Aubrey J. Grant, MD, ABC member, Sports Cardiology specialist; G. Mark Jenkins, MD, Co-Chair, ABC Advisory Group and Former ABC Board Member; Kevin F. Kwaku, MD, PhD, ABC Board Member and Co-Chair, ABC Electrophysiology Committee; Jayne Morgan, MD, Co-Chair, ABC Communications Committee; Anekwe E. Onwuanyi, MD, President of ABC; and Barbara Hutchinson, MD; ABC Board Chair. About ABC Founded in 1974, the ABC is a nonprofit organization dedicated to eliminating the disparities related to cardiovascular disease and achieving health equity such that all people can live long healthy lives. Membership is open to all interested in the care of people with or at risk for cardiovascular disease, including health professionals, lay members of the community (Community Health Advocates), corporate and institutional members. Today, the ABC's public and private partnerships continue to increase its impact in communities across the nation. For more information, visit and wearethefaces.abcardio.org or connect with ABC on Twitter, Facebook, Instagram, and LinkedIn. Contact: ABC Media Relations [email protected] 646-689-0659 SOURCE Association of Black Cardiologists

Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper’s Board of Directors. Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee. Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees. Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures. “Scott is a distinguished pharma industry executive and physician, with deep experience in drug development, particularly in immunology, with several successful approvals and commercial launches to his credit,” said Ron Martell, CEO of Jasper. “We are delighted to welcome Scott to our Board, and look forward to benefiting from his strategic insights and venture perspective as we continue to develop briquilimab for CSU, LR-MDS and stem cell transplant conditioning.” “I am extremely impressed with the strategic direction the Jasper management team and Board have established for briquilimab, as well as the enormous potential the asset has in a broad range of chronic treatment indications,” said Dr. Brun. “I look forward to working with Ron, his leadership team and my colleagues on the Board to further develop briquilimab in multiple disease states.” Dr. Brun has over two decades of drug development and leadership experience in the pharmaceutical industry. He was most recently a Senior Advisor to Horizon Therapeutics and Vice President of Scientific Affairs and Head of AbbVie Ventures. Previously, Dr. Brun served as Vice President and Head of Pharmaceutical Development at AbbVie. During his tenure, Dr. Brun oversaw a global organization that was responsible for AbbVie’s portfolio of early and late-stage pipeline compounds as well as marketed compounds within immunology, oncology, neurology, , renal, infectious disease, and women’s and men’s health. Dr. Brun contributed to the development and approval of a number of products across therapeutic areas, including Skyrisi, Rinvoq, Viekira, Mavyret, Venclexta, and Orilissa. Prior to joining AbbVie, Dr. Brun spent over 15 years at Abbott Laboratories, where he held positions of increasing leadership in drug development within the R&D organization. Dr. Brun is currently acting as an independent consultant and advisor to the venture capital and biopharmaceutical industry. He is a venture partner at the global life science venture capital firm Abingworth, a member of the boards of directors of Axial Therapeutics, Trishula Therapeutics, Forte Biosciences (Nasdaq: FBRX) and Cabaletta Bio (Nasdaq: CABA) and a consultant to a variety of startup companies and academic incubator programs. Dr. Brun received his B.S. in Biochemistry from the University of Illinois at Urbana-Champaign and earned his M.D. from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at www.jaspertherapeutics.com. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, the development of briquilimab for CSU, LR-MDS and stem cell transplant conditioning and chronic treatment conditions, briquilimab’s further development in multiple disease states and the strategic direction for briquilimab. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q . If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com